A separate Prime analysis, however, of year-over-year claims data for Wegovy and Zepbound only found an improvement in ...

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...

Uninsured or self-pay obesity patients can get any dose of Wegovy for $299 from July 1–31, 2025. Patients can get their ...

Novo Nordisk continues to expand its partnerships with telehealth companies to broaden access to its blockbuster weight loss ...

A new expert consensus statement issued by the American College of Cardiology said that cardiologists should “embrace” new weight-loss medications for patients with obesity, TCTMD reported June 25.

Gov. Jeff Landry vetoes a plan to cover costly weight-loss drugs for Louisiana state workers and teachers, citing long-term ...

India's anti-obesity drug market is currently valued at Rs 3,000-3,500 crore & is projected to grow nearly eightfold by 2030, ...

Over 100 cases of acute pancreatitis have been reported to UK health regulators this year, many tied to the newest GLP-1 drug on the market.

Novo Nordisk says the decision was made based on “Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk.” ...

For high-risk patients with type 2 diabetes, oral semaglutide reduced risk for major cardiovascular and ischemic limb-related ...

W. Timothy Garvey, M.D., served as lead author in the clinical trial. A new combination drug therapy is showing extraordinary ...

A clinical guidance from the American College of Cardiology Solution Set Oversight Committee states that pharmacotherapy may ...